Recent Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)
A number of research firms have changed their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX): 12/23/2024 – Neurocrine Biosciences had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock. 12/23/2024 – Neurocrine Biosciences had its price target raised by analysts at Barclays PLC […]
More Stories
GAMMA Investing LLC Raises Position in Eaton Corporation, PLC (NYSE:ETN)
GAMMA Investing LLC raised its position in Eaton Corporation, PLC (NYSE:ETN – Free Report) by 0.7% during the 1st quarter,...
Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by Spire Wealth Management
Spire Wealth Management reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 1.6% in...
Golden State Wealth Management LLC Acquires 974 Shares of Zoetis Inc. (NYSE:ZTS)
Golden State Wealth Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 90.6% in the first...
Zoetis Inc. (NYSE:ZTS) Shares Sold by Bessemer Group Inc.
Bessemer Group Inc. decreased its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 42.6% during the 1st...
Golden State Wealth Management LLC Acquires 4,508 Shares of CSX Corporation (NASDAQ:CSX)
Golden State Wealth Management LLC increased its holdings in shares of CSX Corporation (NASDAQ:CSX – Free Report) by 123.1% in...
Golden State Wealth Management LLC Grows Stake in Meta Platforms, Inc. (NASDAQ:META)
Golden State Wealth Management LLC grew its position in Meta Platforms, Inc. (NASDAQ:META – Free Report) by 151.1% during the...